Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.
Mahrukh M. Syeda(NYU Langone Health), David Polsky(New York University), Sonia Dolfi(Bristol-Myers Squibb (United States)), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Hao Tang(Stanford Health Care), Saim Ali(NYU Langone Health), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Kao-Tai Tsai(Bristol-Myers Squibb (United States)), Jeffrey S. Weber(NYU Langone Health), James Larkin(Trinity College Dublin), Keyur Desai(Bristol-Myers Squibb (United States)), Josephine Alegun(New York University), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sheen Wang(Bristol-Myers Squibb (United States)), Jennifer Wiggins(New York University)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k